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Abstract
Cancer cells activate the biosynthesis of saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) in order to
sustain an increasing demand for phospholipids with appropriate acyl composition during cell replication. We have
previously shown that a stable knockdown of stearoyl-CoA desaturase 1 (SCD1), the main D9-desaturase that converts SFA
into MUFA, in cancer cells decreases the rate of lipogenesis, reduces proliferation and in vitro invasiveness, and dramatically
impairs tumor formation and growth. Here we report that pharmacological inhibition of SCD1 with a novel small molecule
in cancer cells promoted the activation of AMP-activated kinase (AMPK) and the subsequent reduction of acetylCoA
carboxylase activity, with a concomitant inhibition of glucose-mediated lipogenesis. The pharmacological inhibition of
AMPK further decreased proliferation of SCD1-depleted cells, whereas AMPK activation restored proliferation to control
levels. Addition of supraphysiological concentrations of glucose or pyruvate, the end product of glycolysis, did not reverse
the low proliferation rate of SCD1-ablated cancer cells. Our data suggest that cancer cells require active SCD1 to control the
rate of glucose-mediated lipogenesis, and that when SCD1 activity is impaired cells downregulate SFA synthesis via AMPK-
mediated inactivation of acetyl-CoA carboxylase, thus preventing the harmful effects of SFA accumulation.
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Introduction
Cancer cells display a radically modified metabolism that
promotes their continuous proliferation. As part of the metabolic
shift towards macromolecular synthesis to support cell replication,
cancer cells activate the biosynthesis of saturated fatty acids (SFA)
and monounsaturated fatty acids (MUFA) to sustain an increasing
demand for phospholipids of appropriate acyl composition for
membrane biogenesis. Thus, several critical enzymes involved in
de novo fatty acid synthesis have been shown to be overexpressed
in malignant cells: ATP-citrate lyase, required for the production
of cytosolic acetylCoA [1], acetylCoA carboxylase (ACC), the
enzyme that catalyzes the synthesis of malonylCoA, the first
committed step in the synthesis of fatty acids [2,3], and fatty acid
synthase (FAS), which synthesizes SFA [2]. The importance of
fatty acid synthesis for cancer cell proliferation and survival is
highlighted by the fact that the inhibition of any of these enzymes
leads to a halt in cell proliferation and increased cell death [4–9].
However, in spite of the overactivation of the tandem of
biosynthetic enzymes that ultimately renders SFA, abundant
amounts of MUFA are typically found in cancer cells [10–13],
suggesting that the biosynthesis of MUFA is required to ensure
cancer cell proliferation and survival.
Mammalian stearoylCoA desaturases (SCD) are microsomal
enzymes that catalyze the D9-desaturation of saturated acylCoAs
to form monounsaturated derivatives [14]. The expression of
SCD1, the main SCD isoform, is increased in several human
cancers, chemically induced tumors, as well as in oncogene-
transformed cells [1,13,15–18]. We have shown that SCD1
modulates not only the content of MUFA in cancer cells, but
also the overall process of lipogenesis [19]. Remarkably, the
ablation of SCD1 expression reduces cancer cell proliferation and
in vitro invasiveness, and dramatically impairs tumor formation
and growth [19,20]. We have also found that active SCD1 may be
required for neoplastic cells to survive a lipotoxic stress since
SCD1 knockdown increases basal apoptosis and sensitizes the cells
to the cytotoxic effects of excess SFA [19]. SCD1 has also been
identified from a siRNA library as a gene whose suppression
impairs human cancer cell survival, further supporting a functional
link between SCD1 and cancer cell growth [21]. Nevertheless,
despite this growing body of information, the intricate mechanisms
by which SCD1 concurrently modulates lipid metabolism and the
biological features of cancer cells are not known.
The process of lipogenesis in mammalian cells is regulated by
Akt and AMP-dependent protein kinase (AMPK), two major
signaling proteins that control several critical biosynthetic and
catabolic reactions. Akt is a powerful inducer of glucose-mediated
lipogenesis in cancer cells, mainly regulating the activity and
transcription of multiple enzymes of glycolysis and fatty acid
synthesis [22,23]. As part of a feedback loop, the activity of Akt is
modulated by the levels of FAS and SCD1. It was observed that
blockade of FAS activity and ablation of SCD1 expression
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In contrast, AMPK activation by phosphorylation promotes the
downregulation of several lipogenic pathways and activates
energy-supplying reactions such as fatty acid oxidation [25].
One major target of activated AMPK is ACC. Upon phosphor-
ylation by AMPK, ACC activity is decreased resulting in the
inhibition of de novo fatty acids synthesis [26]. The concomitant
reduction of malonylCoA levels promotes the b-oxidation of fatty
acids. SFA are also potent allosteric inhibitors of ACC, providing a
negative feedback loop for the fatty acid biosynthesis [27–29]. We
hypothesize that elevated SCD1, by converting SFA to MUFA, is
able to maintain the pathway of fatty acid synthesis and lipogenesis
fully activated. This condition favors cancer cell growth and
proliferation, hence reducing SCD1 activity should impair these
two biological processes.
Recently, several series of novel D9-desaturase selective small-
molecule inhibitors have been published [30–32]. One of these
SCD inhibitors, CVT-11127 (N-(2-(6-(3,4-dichlorobenzylamino)-
2-(4-methoxyphenyl)-3-oxopyrido[2,3-b]pyrazin-4(3H)-yl)ethyl)
acetamide), is a potent and specific inhibitor of rat microsomal and
HepG2 cell D9-desaturation [30] and may be a potential valuable
tool for studying the regulation of cellular metabolism and
signaling pathways by SCD1 activity.
In our current studies, we show that the acute inhibition of
SCD1 activity with CVT-11127, as well as the chronic deficiency
of SCD1 by stable gene knockdown, significantly impairs de novo
fatty acid synthesis from glucose in human lung carcinoma cells.
We also report that pharmacological inhibition of SCD activity
drastically reduced cellular proliferation in cancer cells, confirming
that SCD1 activity is a crucial requirement for cancer cell growth.
Furthermore, we observed that the blockade of SCD1 activated
AMPK and inactivated ACC resulting in decreased lipogenesis. In
experimental conditions that induce lipogenesis, such as stimula-
tion of ACC with citrate and inhibition of AMPK, a further
decrease in cellular proliferation was observed in SCD1-deficient
cells. In contrast, the pharmacological activation of AMPK
reversed cell proliferation to control levels. As a whole, our data
suggest that the downregulation of fatty acid synthesis when SCD1
activity is low may be an adaptive safeguard mechanism to prevent
the harmful effects of excess SFA when its conversion to MUFA is
impaired. Moreover, these results highlight the importance
of SCD1 in the regulation of neoplastic proliferation and
metabolism.
Materials and Methods
Materials
A549 human lung adenocarcinoma cells and WS-1 human
fibroblasts were obtained from the American Type Culture
Collection (Rockville, MD, USA). H1299 human lung cancer
cells and MCF-7 human breast cancer cells were generously
provided by Dr C. S. Yang and Dr Wendie Cohick, Rutgers
University, NJ, respectively. Dulbecco’s modification of Eagle’s
medium (DMEM) with L-glutamine, MEM vitamin mixture and
MEM nonessential amino acid solution were from Mediatech
Cellgro (Manassas, VA, USA). Minimum Essential Medium
(MEM) containing Earle’s salts and L-glutamine, glucose free
DMEM, phenol red free MEM, trypsin-EDTA solution and
Lipofectamine
TM 2000 transfection reagent were purchased from
Invitrogen Corporation (Carlsbad, CA, USA). Heat-inactivated
fetal bovine serum, crystal violet, protease and phosphatase
inhibitor cocktail 2, fatty acid free bovine serum albumin,
monoclonal anti b-actin antibody, AICAR, coenzyme A, ATP,
NADH and dimethyl sulphoxide (DMSO) were from Sigma-
Aldrich (St. Louis, MO, USA). Nitrocellulose membrane, HPLC
grade solvents, phosphate-buffered solution without calcium and
magnesium and other cell culture supplies were obtained from
Thermo Fisher Scientific (Pittsburgh, PA, USA). Anti phospho-
AMPKa (Thr172) and phospho-ACC (Ser79) antibodies were
obtained from Cell Signaling Technology Inc (Danvers, MA,
USA). HRP-conjugated anti mouse and anti rabbit IgG were from
Santa Cruz Biotechnologies (Santa Cruz, CA, USA). D-[U-
14C]glucose, [1-
14C]stearic acid, and [1-
14C]sodium acetate were
purchased from American Radiolabeled Chemicals, Inc (St. Louis,
MO, USA). [Methyl-
3H]thymidine, [2-
3H]deoxyglucose and full-
range rainbow molecular weight marker were from GE Health-
care Bio-Sciences Corp (Piscataway, NJ, USA). Lactate assay kit
was from Eton Biosystems Inc (San Diego, CA, USA). BCA
Bradford protein assay kit and super signal West pico chemilu-
minescent substrate were from Pierce (Rockford, IL, USA).
Compound C was from Calbiochem (San Diego, CA, USA).
Cell culture
WS-1, A549 and MCF-7 cells were cultured in MEM and
H1299, H460 and MDA-MB-231 cells were grown in DMEM.
Media was supplemented with 10% FBS, penicillin (100 U/ml),
streptomycin (10 mg/ml), 1% non essential amino acids and 1%
MEM vitamin solution (growing medium). Cells were grown at
37uC, 5% CO2, and 100% humidity.
Cell models of SCD1 inhibition
A stable transfected clonal population of A549 cells bearing an
antisense sequence of the human SCD1 gene (hSCDas) has been
described previously [20]. In addition, pharmacological inhibition
of SCD activity was assessed with novel chemical SCD inhibitor,
CVT-11127 (N-(2-(6-(3,4-dichlorobenzylamino)-2-(4-methoxyphe-
nyl)-3-oxopyrido[2,3-b]pyrazin-4(3H)-yl)ethyl) acetamide), whose
synthesis and structure were described elsewhere [30]. CVT-
11127 was used at concentrations in which the inhibition of SCD1
was greater than 95%. The total incubation time with the SCD
inhibitor was, at least, 24 h in order to allow for one cell
population doubling.
SCD activity and de novo fatty acid synthesis
D9 desaturase activity in whole cells was determined as
previously described [19]. Briefly, subconfluent cell monolayers
were incubated with the specified concentration of SCD inhibitor
or DMSO vehicle in the growing media for 24 h. Six hours prior
harvesting, the cells were pulsed with [
14C]stearic acid (0.25 mCi/
60 mm petri dish) in culture medium containing 0.5% bovine
serum albumin. Total cellular lipids were extracted according to
Bligh & Dyer [33] and transesterified with BF3 in methanol for 3 h
at 64uC under nitrogen atmosphere. The methyl esters were
separated by argentation thin layer chromatography (TLC)
following the procedure described by Wilson and Sargent [34],
using a solvent phase consisting of hexane:ethyl ether (90:10, by
vol). The radiolabeled stearic and oleic acids were detected with a
Storm scanner (Molecular Dynamics) and its optical density
quantified with Imagequant software. For de novo fatty acid
synthesis, the cells were incubated for 6 to 24 h with [U-
14C]glu-
cose or for 24 h with [
14C]sodium acetate in the presence or
absence of the SCD inhibitor. Cellular lipids were extracted as
described and the amount of [
14C]tracer incorporated into lipids
was normalized to cellular protein content of cells grown in
parallel petri dishes. Aliquots of [
14C]glucose-labeled cell lipids
were esterified and the levels of radiolabeled SFA and MUFA were
determined by TLC as described above.
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Preconfluent H1299 cells were incubated with 1 mM CVT-
11127 or vehicle in glucose-deficient DMEM for 24 h. Cell were
then pulsed for 7 minutes with 0.5 mCi/dish [
3H]deoxyglucose in
DMEM containing 0.5% BSA, 25 mM HEPES and 100 mM
glucose. Labeled medium was quickly removed and residual
labeling on the monolayers was removed by three washes with ice-
cold PBS. Total radioactivity of cell homogenates was counted in a
scintillation counter and [
3H]DPM were normalized to cell protein
content.
Total cellular fatty acid composition
Total cellular lipids from A549 and H460 cancer cells treated
with 10 uM or 1 uM CVT-11127, respectively, or vehicle for 24 h
were extracted as described above. Heptadecanoic acid (C17:0)
was added as internal standard at the beginning of the lipid
extraction process. Transesterification and methylation of fatty
acids from total lipids were performed as described by Lepage and
Roy [35]. Fatty acid methyl ester composition was determined by
gas chromatography using a Varian 3800 GC (Varian Inc, Palo
Alto, CA), equipped with a DB-23 column (J&W Scientific Inc.,
Folsom, CA) and FID. Fatty acid methyl ester identification and
response factors were determined using standard mixtures
(NuChek Prep Inc., Elysian, MN). Chromatographic peaks were
identified by comparison of their retention times with those of pure
fatty acid standards and percent distribution was calculated.
[
3H]Thymidine incorporation into cell DNA
The rate of DNA synthesis was estimated by determining the
levels of [
3H]thymidine incorporation into DNA after pulsing the
cells with the radiolabeled tracer for 2 h, followed by precipitation
of total DNA and scintillation counting, as described [36]. Groups
of cells were incubated with glucose free DMEM supplemented
with different concentrations of glucose for 22 h prior the addition
of the [
3H]thymidine. In other experiments, the growing media
was supplemented with 10 mM sodium pyruvate or sodium citrate
for 22 h. For SCD inhibition, CVT-11127 was added at the
indicated doses to the growing media for 22 h prior the labeling
period. In all cases, the total incubation time with the metabolites
or the inhibitor was 24 h.
Determination of cell growth curves
The cells were seeded in 12 well plates (14,000 cells per well).
Twenty four hours later, the monolayers were rinsed with PBS and
groups of cells were incubated with 0.5 or 5.5 mM glucose in the
growing media. The media was changed every 48 h thereafter.
For some experiments, cells were incubated for 24 h and 48 h with
increasing concentrations of sodium oleate up to 100 mM. Cellular
proliferation was estimated by crystal violet staining following the
procedure described by Menna et al. [37], with modifications.
Briefly, cells were fixed with methanol, stained with 0.1% crystal
violet in distilled water and rinsed three times with water. The dye
in the stained cells was solubilized in 10% methanol, 5% acetic
acid solution and quantified by spectrophotometry at 580 nm.
The value of a blank well was subtracted in each case. The values
at different time points were normalized to the data at 24 h after
seeding to avoid differences due to disparity in cell adhesion
efficiency or cell death.
Lactate measurement
To determine the production of lactate, 9610
4 cells were seeded
in 6 well plates and grown until monolayers reached 80%
confluency. Cells were then rinsed with PBS and grown in
10%FBS, phenol-free MEM with the indicated concentrations of
SCD inhibitor or vehicle for 24 h. For some determinations, the
cells undergoing a blockade of SCD activity were incubated with
10 mM sodium citrate for 24 h. The content of lactate in the
conditioned media was quantified with a lactate assay (Eton
Biosciences Inc), according to the manufacturer’s instructions and
normalized to the total cellular protein.
Immunoblotting
Preconfluent cells were treated as described, rinsed with ice cold
PBS, scraped in cold hypotonic lysis buffer (20 mM Tris-HCl
pH 7.5, 10 mM NaF, 1 mM EDTA, plus protease and phospha-
tase inhibitor cocktails) and sonicated. Fifty micrograms of total
cellular proteins were resolved by SDS-PAGE and transferred
onto a nitrocellulose membrane. After blocking, the membranes
were incubated with polyclonal rabbit phospho-AMPKa (Thr172)
and phospho-ACC (Ser79) overnight or monoclonal mouse anti b-
actin for 2 h in 1:1,000 dilutions. Horseradish peroxidase-
conjugated secondary antibodies were used in 1:10,000 dilutions.
Proteins on the membrane were detected using a West pico
chemiluminescence detection kit and quantified with a ChemiDoc
(BioRad) digital image system using a QuantityOne software. All
analyses of protein band density were done in the linear portion of
the saturation curves and normalized to the b-actin content of the
same samples.
Determination of cellular protein
Total cellular protein content was measured by Bradford
method, using BSA as a standard.
Statistical analysis
Results from a representative experiment with at least 3 samples
per experimental group are presented as means6S. D. Statistical
significance of the data was determined by Student’s t-test.
Results
Pharmacological inhibition of SCD activity impairs
proliferation of cancer cells
We have previously reported that chronic depletion of SCD1
decreases the rate of cell proliferation in oncogene-transformed
and cancer cells [19,20]. To evaluate the potential use of newly
developed SCD inhibitors as novel anticancer agents, we tested the
potential growth inhibitory effect of CVT-11127, a novel small-
molecule inhibitor of SCD activity, on several lung cancer cell
lines. This compound was found to be an effective and desaturase-
selective blocker of SCD activity in rat liver microsomal
preparations and human HepG2 cells [30]. These authors
reported that CVT-11127 does not inhibit the activity of rat
microsomal D5 and D6 desaturases at concentrations up to
30 mM, indicating that CVT-11127 is selective for D9 desaturases.
Thus, we incubated A549, H1299 and H460 cells with increasing
concentrations of the SCD inhibitor for 24 h and found a
progressive decrease in the rate of cell replication of cancer cells
with respect to vehicle (DMSO)-treated cells (Figure 1). H1299
cells showed ,55% and 65% decrease in cell proliferation rate in
presence of 1 mM and 5 mM CVT-11127, respectively (Figure 1A).
A549 cells were less sensitive to the cell growth inhibitory effect of
CVT-11127, since these cells reduced their replication rate by
20% and 40% when treated with 5 mM and 10 mM CVT-11127,
respectively (Figure 1B). Moreover, the proliferation rate of H460
cells treated with CVT-11127 was 60% lower than vehicle-treated
controls (Figure 1C), indicating that these cells are as sensitive to
the antigrowth effect of the SCD inhibitor as H1299 cells.
SCD1 Inhibition in Cancer
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and H1299 (B) cells were incubated with with different concentrations of CVT-11127 (CVT) or DMSO vehicle for 24 h, as described, and cell
proliferation was determined by Crystal violet assay. For a similar analysis, H460 cells (C) were treated with 1 mm CVT-11127 for 24 h. For the
determination of DNA synthesis, A549 (D) and H460 (E) cells were incubated with 10 mM and 5 mM CVT-11127 or vehicle for 24 h and pulsed with
[
3H]thymidine (1 mCi/dish) for 2 h at 37uC. Total [
3H]-labeled DNA was precipitated, radioactivity was quantified in a scintillation counter and
normalized to protein concentration. F, MCF-7 and MDA-MB-231 breast cancer cells, and WS-1 human skin fibroblasts were incubated with 10 mM
CVT-11127 (CVT) or DMSO vehicle for 24 h and cell proliferation was assessed by crystal violet staining method. E, H460 cells were incubated for 48 h
with 1 mM CVT in presence of 1, 10, 50 and 100 mM sodium oleate complexed with BSA (1:2 BSA:fatty acid ratio). Cell incubated with DMSO vehicle
were considered the control group. Cell growth was estimated by crystal violet staining method. Values represent the mean6S.D. of triplicate
determinations. *, p,0.05 or less vs control, by Student’s t test.
doi:10.1371/journal.pone.0006812.g001
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profound reduction (,60%) in the incorporation of [
3H]thymidine
into newly synthesized DNA, an early marker of cellular
proliferation rate, in both A549 and H1299 cancer cell lines
(Figure 1D and E). In order to verify that the antigrowth effect of
the SCD chemical inhibitor was not cell type-specific, MCF-7 and
MDA-MB-231 breast cancer cells, as well as in normal human
WS-1 fibroblasts, were incubated with CVT-11127 for 24 h and
cell proliferation was assessed by Crystal violet staining (Figure 1F).
It was found that the breast cancer cells were similarly sensitive to
the cytostatic action of the small molecule SCD inhibitor.
However, the proliferation of WS-1 normal skin fibroblasts was
not affected by the treatment, suggesting that the antigrowth effect
of SCD blockade may be dependent on the rate of cell replication.
Furthermore, increasing concentrations of oleate in cell culture
medium partially or totally reversed the inhibition of cell
proliferation in H460 cells incubated with the small molecule
SCD inhibitor (Figure 1G). Similar results were obtained with
H1299 cells (data not shown). These findings indicate that oleic
acid is essentially required for the fully active replication of cancer
cells.
As expected, the growth inhibitory action of CVT-11127 was
positively correlated with a significant inhibition of SCD activity in
the lung cancer cells. As shown in Figure 2A–C, the treatment of
A549 and H1299 cells for 24 h with 10 mM and 5 mM of CVT-
11127, respectively, reduced SCD activity more than 95%, as
assayed by the production of [
14C]oleic acid from its radiolabeled
precursor, stearic acid. This confirms that CVT-11127 is highly
effective at suppressing the very high SCD activity found in these
cancer cell lines.
As a result of the reduction of SCD1 activity by the small
molecule inhibitor, the distribution of SFA and MUFA in total
cellular lipids of A549 cells was considerably altered (Figure 3A
and B). The ratios MUFA to SFA in both n-7 and n-9 fatty acid
series was decreased by 25% and 35%, respectively, in cells treated
for 24 h with CVT-11127 with respect to vehicle-treated controls.
In addition, the ratios MUFA/SFA in H460 cells were found
diminished by 47% (n-7MUFA/SFA) and 60% (n-9MUFA/SFA)
in cells undergoing a similar treatment with CVT-11127 with
respect to DMSO-treated cells (Figure 3C and D). Perturbations in
the cell MUFA content by incubations with the small molecule
inhibitor were observed as early as 1 h after treatment (data not
shown). These observations clearly show that the total fatty acyl
chain composition of lipids in cancer cells is under the control of
SCD1 activity, even when these cells were cultivated in medium
with FBS, which contains significant amounts of MUFA.
Inhibition of SCD1 decreases de novo lipid synthesis from
glucose
Cancer cells have modified a set of signaling and metabolic
pathways to enhance the use of glucose as main substrate for
macromolecular biosynthesis and for energy-generating reactions
[38]. Previously, we showed that chronic depletion of SCD1
suppresses the overall rate of lipogenesis [19,20]. In order to
dissect the mechanisms of metabolic regulation by SCD1, we
investigated the effect of acute inhibition of SCD activity with the
novel small molecule CVT-11127 on the lipogenic pathways. To
document the effect of acute SCD inactivation on glucose-
mediated lipid biosynthesis, A549 and H1299 cells were treated
with SCD inhibitor or vehicle for 6 h and 24 h respectively, and
the formation of total cellular lipids from [
14C]glucose was
determined. As displayed in Figure 4A and B, the incorporation of
radiolabeled glucose into total cellular lipids was significantly
impaired (30%) in SCD inhibitor-treated H1299 and A549 cells
with respect to vehicle-treated controls. As previously observed
[20], the incorporation of radiolabeled glucose into total lipids
decreased by ,20% in stable SCD1-knockdown A549 (hSCDas)
cells (Figure 4C), confirming that the presence of a fully active
SCD1 is crucial for sustaining the accelerated glucose-mediated
lipogenesis in cancer cells. The alteration in the formation of
[
14C]glucose-labeled lipids was not caused by a deficient uptake of
glucose because we observed no changes in the rate of
[
3H]deoxyglucose uptake in cells treated with CVT or vehicle
(Figure 4D). Incorporation of radiolabeled glucose into the fatty
acids of cancer cell lipids was reduced by treatment with CVT
(Figure 4E), suggesting that the abnormal formation of lipids in
cells undergoing inhibition of SCD1 may be caused by a defective
de novo fatty acid biosynthesis. As expected, the production of
glucose-labeled MUFA was almost fully suppressed in H1299 cells
with a block in SCD activity (Figure 4E, upper panel).
Furthermore, the biochemical alteration in lipogenesis in cells
with chemical blockade of SCD appears to be located downstream
the formation of acetylCoA since a reduced formation of
[
14C]acetate-labeled lipids was observed in CVT-treated H1299
cells with respect to vehicle-treated controls (Figure 4F).
Figure 2. Specific inhibition of SCD activity by CVT-11127 compound. For the determination of D9-desaturating activity in cancer cells, A549
(A, B) and H1299 cells (A, C) were treated for 24 h with 10 mM and 5 mM CVT respectively, or DMSO vehicle. Six hours before harvesting, the cells were
pulsed with [
14C]18:0 (0.25 mCi/dish). After conversion into methylesters, fatty acids were separated on silver nitrate-impregnated TLC plates. The
radioactive spots corresponding to SCD substrate and product ([
14C]18:1), were visualized with a Phosphor Imager (A) and quantified by
densitometric analysis (B and C). Values represent the mean6S.D. of triplicate determinations. *, p,0.05, by Student’s t test.
doi:10.1371/journal.pone.0006812.g002
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decreased proliferation of SCD1-deficient cells
As described above, both acute pharmacological blockade of
SCD activity and stable gene knockdown of SCD1 significantly
alter the rates of glucose-mediated lipogenesis and cell replication.
We hypothesized that a perturbation in aerobic glycolysis could be
the primary cause of the impaired proliferation and survival of
SCD1-deficient cells ([19,20] and Figure 1). We then determined
the rate of glycolysis in A549 and H1299 cells by assessing the
levels of lactate in the conditioned media, an indicator of aerobic
glycolytic rate in cancer cells [39], and found an increase of 30–
60% in cells undergoing pharmacological inhibition of SCD
compared with vehicle-treated controls (Figure 5A). To confirm
that a change in the flux of glycolytic metabolites was not
responsible for the deficient replication of SCD1-ablated cells, we
incubated the cells in medium containing very low (0.5 mM),
normal (5.5 mM) or high (25 mM) levels of glucose and
determined the rate of DNA synthesis and cell growth. As shown
for other cancer cell lines, A549 cells displayed strict glucose
dependence for proliferation (Figure 5B). When grown in
essentially glucose-free MEM (containing ,0.5 mM glucose from
the 10% FBS-supplementation) for 24 h, the incorporation of
radiolabeled thymidine into the DNA of SCD1-deficient (hSCDas)
and control cells was reduced by 70% when compared to cells
growing under standard culture conditions (5.5 mM glucose).
However, the significantly decreased rate of DNA synthesis
observed in SCD1-ablated cells persisted regardless of the glucose
level in the culture media. These differences in cell growth rate
between SCD1-deficient cells and controls, grown in both low and
normal glucose-containing media, were maintained over a course
of 96 h incubation (Figure 5C). Furthermore, not even the
presence of 25.5 mM glucose in the growth media was able to
reverse the reduced rate of DNA synthesis of SCD1 deficient cells,
suggesting that the abnormally low rate of replication of cells with
reduced SCD1 can not be attributed to an altered utilization of
glucose. Alternatively, we incubated the hSCDas and control cells
with 10 mM pyruvate, the end product of glycolysis and fuel for
the tricarboxylic acid cycle, for 24 h and examine DNA formation.
As shown in Figure 5D, pyruvate was ineffective for inducing
DNA synthesis in either cell group, or restoring the impaired
Figure 3. Decreased MUFA/SFA ratio in total lipids of lung cancer cells treated with a small molecule inhibitor of SCD activity. A549
cells (A, B) and H460 cells (C, D) were incubated with 10 mM and 1 mM CVT-11127 (CVT), respectively, or DMSO for 24 h. Cellular lipids were extracted
and fatty acids were converted to their methylester form by transesterification as described in Materials and Methods. Fatty acid methyl ester
composition was assessed by gas chromatography and percent distribution of fatty acids was calculated. Values express the ratio 18:1n-9/18:0 (A, C)
and 16:1-n7+18:1n-7/16:0 (B, D), and represent the mean6S.D. of 4–5 samples. *, p,0.01 or less, by Student’s t test.
doi:10.1371/journal.pone.0006812.g003
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10 mM and 1 mM CVT-11127 (CVT), respectively, or DMSO for 24 h. Cells were then pulsed with 1 mCi D-[U-
14C]glucose for up to 24 h. C, A549 cells
with a stable knockdown in SCD1 expression (hSCDas) and mock-transfected control cells were subjected to a similar incubation with [
14C]glucose.
Cellular lipids were extracted and incorporation of [
14C]glucose into total lipids was quantified by scintillation counting and normalized to protein
concentration. D, basal glucose uptake was assayed in H1299 cells treated with 1 mM CVT or vehicle for 24 h by estimating the uptake of
[
3H]deoxyglucose. E, H1299 cells were incubated with [
14C]glucose in presence or absence of 1 mM CVT for 6 h and levels of total [
14C]fatty acids, as
well as radiolabeled SFA and MUFA (upper panel), were determined by argentation TLC as described in Materials and methods. F, the rate of lipid
synthesis in H1299 cells was assessed by incubation with 1 mM CVT or vehicle and 0.5 mCi/dish of [
14C]acetate for 24 h. Lipids were extracted and
radioactivity of total lipids was determined by scintillation counting. Values represent the mean6S.D. of triplicate determinations. *, p,0.05 or less,
by Student’s t test.
doi:10.1371/journal.pone.0006812.g004
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finding further confirms that the alteration in lipogenesis and cell
growth caused by the inhibition of SCD1 can not be ascribed to
deficient production of glycolytic products.
Inhibition of SCD1 induces AMPK and reduces ACC
activity
Cellular growth and proliferation depends on the coordinated
and opposed regulation of anabolic and catabolic pathways.
AMPK, a central cell fuel sensor, is activated upon energy
deficiency and by other conditions of cellular stress [25]. One of
the main metabolic targets of the AMPK pathway is ACC.
Phosphorylation of ACC by AMPK reduces its activity with the
consequent decrease in de novo fatty acid synthesis. We therefore
determined whether the activation of these catabolic signals could
account for the reduced lipogenesis in our cellular models of SCD1
deficiency. Initially, we assessed the effect of the pharmacological
SCD inhibitor CVT-11127 on AMPK activation in H1299 and
A549 cells. After 24 h treatment, the levels of the phosphorylated
AMPK a-subunit and ACC were analyzed by immunoblotting. As
shown in Figure 6A and B, and in agreement with the observed
decrease in lipogenesis, the blockade of SCD activity resulted in
increased phospho-AMPK in both cancer cell lines as well as in an
increase in phospho-ACC in H1299 cells treated with the SCD
inhibitor. Furthermore, in A549 cells with the stable knockdown of
SCD1 expression, phosphorylation of ACC-a was greater that in
mock-transfected control cells (Figure 6C). As positive control for
the downregulation of AMPK in this experiment, some cells were
treated with compound C, a well known blocker of AMPK
phosphorylation, which showed a notable reduction on phospho-
ACC. Morover, the phosphorylation of ACC was also significantly
augmented (,80%) in hSCDas cells, indicating that AMPK
activity was effectively induced in a condition of SCD1 deficiency.
Incubation of SCD1-deficient cells with palmitic acid did not
Figure 5. Induction of glycolysis/lipogenesis does not rescue the reduced proliferation of cells with depleted SCD. A, A549 and H1299
cells were incubated with 10 mM and 5 mM CVT-11127 (CVT) respectively, or vehicle (DMSO) in phenol red-free media for 24 h. The lactate
concentration in the conditioned media was determined with a colorimetric kit as described under Experimental procedures and normalized to
cellular protein. Control and SCD1-deficient (hSCDas) A549 cells were incubated with the indicated concentrations of glucose (GLU) (B) or pyruvate
(C) for 24 h and pulsed with [
3H]thymidine (1 mCi/dish) for 2 h at 37uC. Total [
3H]-labeled DNA was precipitated, radioactivity was quantified in a
scintillation counter and normalized to protein concentration. D, growth curve of control and hSCDas A549 cells in media containing either 0.5 or
5.5 mM glucose. Cells were seeded in 12 well plates (14,000 cell/well) and after 24 h regular growing media was switched to glucose-supplemented
media. Media were replaced with fresh glucose-supplemented media every 48 h thereafter. At the indicated times, cell population was determined
by crystal violet staining as described under Experimental procedures. Values represent the mean6S.D. of triplicate determinations. *, p,0.05, by
Student’s t test.
doi:10.1371/journal.pone.0006812.g005
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PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6812Figure 6. Inhibition of SCD1 upregulates AMPK phosphorylation and activity. A549 and H1299 cells were incubated with 10 mM and 5 mM
CVT-11127 (CVT) respectively, or DMSO for 24 h. The levels of phospho-ACC (Ser79) and phospho-AMPKa (Thr172) were determined by Western Blot
in CVT-11127-treated cells (A–B) and SCD1-deficient A549 cells (C) and normalized to b-actin content. Cells treated with 20 mM Compound C (CpC)
were included as a control. D, regulation of ACC activity by fatty acids. SCD1-deficient (hSCDas) and control A549 cells were serum-starved (0.1% FBS)
for 24 h and incubated for 30 min in serum-depleted media with or without 100 mM palmitic (Pal) or oleic (Ole) acid complexed with 0.5% w/v fatty
acid-free bovine serum albumin (BSA). Cellular levels of phospho-ACC (Ser79), phospho-AMPK and b-actin were determined by Western blot. Values
represent the mean6S.D. of triplicate determinations. *, p,0.05 or less, by Student’s t test.
doi:10.1371/journal.pone.0006812.g006
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however, oleic acid significantly reduced the levels of phosphor-
ACC (Figure 6D). Overall, these results suggest that the inhibition
of SCD1 suppresses lipogenesis by the induction of AMPK
pathway and the consequent inactivation of ACC.
Is activation of AMPK pathway upon SCD1 inhibition a
protective mechanism in cancer cells?
Although high rates of de novo fatty acid synthesis are necessary
for active cellular proliferation [40], the accumulation of SFA has
been shown to be deleterious for both normal and cancer cells
[19,41–44]. We have previously reported that SCD1-deficient cells
display an increased content of SFA in all major lipid species,
including the non-esterified fatty acid fraction, a condition that
triggers the program of cell death [19,41]. Thus, we speculated
that the activation of AMPK and the consequent inhibition of fatty
acid synthesis could ultimately be a protective mechanism against
the accumulation of SFA due to deficient SCD1 activity.
Therefore, we examined the rate of DNA synthesis in cancer cells
upon either inhibition or stimulation of AMPK activity. As
expected, the blockade of AMPK activity by compound C
translated into a notable reduction in ACC phosphorylation
(Figure 7A). Treatment with compound C provoked a reduction in
DNA synthesis in both control and SCDas cells, although this
decrease was more profound in SCD1-deficient cells (Figure 7B). A
similar depressing effect in the rate of DNA formation was also
Figure 7. Inhibition of AMPK further reduces cellular proliferation in cells with a blockade in SCD1. A, control and SCD1-deficient A549
cells were incubated with compound C (20 mM), AICAR (0.25 mM) or vehicle for 24 h and the levels of phospho-ACC (Ser79) were estimated by
Western Blot. Protein bands were quantified by densitometric analysis and normalized to b-actin content. hSCDas and mock-transfected control cells
(B), or CVT-11127-treated (CVT) H1299 (C) and A549 (D) cells were treated with Compound C, AICAR or vehicle and pulsed with [
3H]thymidine for 2 h.
The radiolabeled DNA was quantified as described in Materials and methods. Results are expressed as fold-change in total [
3H]DNA levels over
vehicle-treated control. Values represent the mean6S.D. of triplicate determinations. *, p,0.05 vs DMSO under the same conditions; #,p ,0.05 vs
CVT treated cells incubated with vehicle by Student’s t test.
doi:10.1371/journal.pone.0006812.g007
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compound C (Figure 7C–D). Conversely, AICAR, a well-studied
pharmacological activator of AMPK, restored the impaired
cellular proliferation of SCD1-deficient A549 cells to control
values (Figure 7B). This set of studies suggests that the activation of
AMPK may be part of a mechanism that shuts down fatty acid
synthesis when conversion of SFA into MUFA is not appropriately
operating.
With the aim of testing whether this effect was due to the
specific modulation of fatty acid synthesis, we incubated the cells
with an excess of citrate (10 mM), a potent allosteric activator of
ACC and a metabolite that provides cytosolic acetylCoA for de
novo fatty acid synthesis. Incubations with citrate led to a
significant increase in incorporation of [
14C]acetate into fatty
acids in both control and SCD deficient cells (data not shown), an
effect likely due to an induction of ACC activity. The amount of
[
14C]SFA was further augmented upon induction of fatty acid
synthesis by citrate in SCD1-ablated cells with respect to control
A549 cells (Figure 8A) indicating citrate was able to overcome the
block in fatty acid synthesis resulting from SCD deficiency. To
assess a potential effect of increased SFA synthesis on the rate of
mitogenesis we determined the levels of DNA synthesis in hSCDas
and control cells in presence or absence of citrate (Figure 8B). In
control cells, citrate treatment had minimal effect on cellular
proliferation (0 to 15% reduction in thymidine incorporation),
while in SCD1-deficient cells the decrease was $30% with respect
to vehicle-treated cell counterparts. This demonstrates that while
citrate can increase SFA production in the absence of SCD1
activity, the increased concentration of SFA is not beneficial and
adds to the anti-proliferative effects of SCD1 deficiency.
Additionally, we investigated the effect of 10 mM citrate
supplementation on the replication of H1299 cells, treated with
the SCD inhibitor or vehicle, for 24 h (Figure 8C). Again, a
significant reduction in proliferation was observed in cells treated
with citrate, CVT-11127 or both, however, the combination of
citrate and the SCD inhibitor led to the most profound reduction
in cell growth. An accumulation of cytosolic citrate could also
hinder glycolysis by suppressing phosphofructokinase activity [45],
thereby inhibiting cell growth. However, the decrease in cellular
proliferation in SCD1-deficient cells was not due to a reduction in
glycolysis since the production of lactate, a terminal product of
glycolysis, was increased upon citrate treatment (data not shown),
arguing in favor of a greater channeling of citrate towards SFA
synthesis due to the activation of ACC.
Discussion
In the present work, we demonstrate that SCD1, a key enzyme
in the biosynthesis of MUFA, controls glucose-mediated lipogen-
esis by modulating the rate of synthesis of fatty acids, thereby
providing cancer cells with the necessary lipid structures and
signals to sustain their fast replication rate. The conversion of
glucose into lipogenic substrates is a critical metabolic event in
cancer cells [38]. The increasing demand of lipid metabolites for
membrane production in cancer cells is met by the concerted
upregulation of the enzymes of both glycolysis and de novo fatty
acid biosynthetic pathways [9,38,40]. High activity levels of ATP-
citrate lyase, ACC and FAS, which respectively catalyzes the
sequential synthesis of acetylCoA, malonylCoA and palmitic acid,
have been shown to be essential for cancer cell proliferation [4–9].
Previous reports from our laboratory [19,20] and the present
studies show that the subsequent conversion of endogenously
synthesized SFA into MUFA by SCD1 is an essential step in
cancer cell growth.
Our results reveal that SCD1 regulates de novo fatty acid
synthesis in cancer cells by modulating ACC activity. The
carboxylation of cytosolic acetylCoA to form malonylCoA by
ACC is the committed step in de novo fatty acid synthesis [46]. As
expected for a rate limiting enzyme, ACC is tightly regulated at
multiple levels [47]. Although we can not completely rule out some
degree of transcriptional regulation of ACC in conditions of
reduced SCD1, especially in the stable SCD1-knockdown cells, its
long half-life (,3 days) [48] suggests that a different regulatory
mechanism is operating under SCD1 inhibition. At least two
interactive posttranslational modifications, polymer-monomer
transition and reversible phosphorylation, determine the rate of
ACC activity. ACC exists as either active polymer or inactive
monomers [49]. AcylCoAs are potent allosteric inhibitors of ACC,
inducing its depolymerization [27–29]. The most potent inhibitors
are saturated fatty acyl-CoAs with 16–20 carbons at ,1 to 6.5 nM
concentrations. Therefore, the elevated intracellular levels of SFA
in cells with reduced SCD1 [19,20] may promote the depolymer-
Figure 8. Citrate induces SFA synthesis and reduces proliferation in SCD1-deficient cells. A, Control and hSCDas cells were incubated
with or without 10 mM sodium citrate for 24 h in the presence of 0.45 mCi/dish [1-
14C]acetate. The total cellular lipids were extracted and
transesterified as described under Materials and Methods. The radiolabeled SFA were resolved on silver nitrate-impregnated TLC plates, visualized
with a Phosphor Imager and quantified by densitometric analysis. B, Control and hSCDas cells were incubated with or without 10 mM sodium citrate
for 24 h and pulsed with [
3H]thymidine for 2 h. The radiolabeled DNA was quantified as described. Values are the mean6S.D. of triplicate
determinations. *, p,0.05 vs control; #,p ,0.05 vs no citrate, by Student’s t test. C, H1299 cells were incubated for 24 h with 5 mM CVT-11127 (CVT)
or DMSO vehicle in growing media with or without 10 mM sodium citrate. Cellular proliferation was estimated by Crystal violet staining. Bars
represent the mean6S.D. of triplicate determinations. *, p,0.05 vs DMSO; #,p ,0.05 vs CVT without citrate, by Student’s t test.
doi:10.1371/journal.pone.0006812.g008
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downregulation of lipid synthesis.
Our data also suggest that SCD1 activity may contribute to the
enhancement of lipid biosynthetic reactions in cancer cells by
inactivating catabolic regulators such as AMPK. In conditions of
low cellular energy or metabolic stress, AMPK is activated by
phosphorylation of its a-subunit [50]. A main metabolic target for
AMPK is ACC. Phosphorylation of serine residues in ACC by
active AMPK inhibits its catalytical activity by both decreasing its
Vmax and increasing the Ka for citrate its allosteric activator
[51,52]. Both stable SCD1 gene knockdown and acute pharma-
cological inhibition of SCD induced AMPK activation and the
subsequent phosphorylation of ACC in lung cancer cells,
suggesting a second mechanism for the inhibition of fatty acid
synthesis and lipogenesis observed in SCD1-deficient cells [19,20].
Interestingly, SCD1 knockout mice exhibit increased AMPK
activity in liver and muscle [53,54], indicating that an SCD1-
mediated regulation of AMPK operates in human and mouse
tissues. Furthermore, the activation of AMPK may be responsible
for other antilipogenic effects of SCD1 ablation in neoplastic
human cells, such as the decreased synthesis of cholesterol [19]. In
this regard, it has been reported that AMPK phosphorylates and
inactivates HMG-CoA reductase a critical enzyme in cholesterol
synthesis [26].
The mechanisms by which SCD1 regulates AMPK are
currently unknown. Our results rule out a relevant role for
LKB1, one of the protein kinases that modulate AMPK activation,
since A549 cells do not express active LKB1 whereas H1299 cells
display an active form of this tumor suppressor [55]. Moreover,
although there is some discrepancy in the literature [56,57],
increased cellular acylCoAs, specially palmitoylCoA, a key
substrate for SCD1 and likely elevated in SCD1 deficient cells
[19], was linked to greater levels of catalytically active AMPK in
several tissues [26,58–60]. Our observation that oleic acid induces
a dephosphorylation of ACC further reinforces the arguments in
favor of a role of MUFA on ACC activation.
A remarkable biological effect of the stable depletion of SCD1 is
the suppression of the malignant phenotype of neoplastic cells,
characterized by a dramatic reduction in cell proliferation and in
vitro invasiveness [19], the activation of programmed cell death
[19,21] and a reduction in the tumorigenic capacity [20]. Here we
observed that the acute inhibition of SCD (,95% reduction after
24 h treatment) with a specific small molecule inhibitor drastically
reduced the rate of proliferation of a variety of human lung and
breast cancer cell lines. Since the activation status of p53, pRb,
and LKB1 as well as other oncogenes and tumor suppressors
varies among these cell lines, the consistent decrease in the rate of
proliferation of SCD1-deficient cells suggests that SCD1 is
involved in a crucial metabolic step that is common to many
cancer cell types. This finding also provides compelling evidence
that SCD inhibitors may have a future role in the treatment of
some cancers.
The aforementioned perturbations in the biological phenotype
of cancer cells induced by a blockade of SCD1 are likely caused, at
least in part, by a deficient production of membrane-building
molecules such as phospholipids and cholesterol to support the
continued proliferation of these cells [19,20]. Active biosynthesis of
lipids is required not only for sustaining continue mitogenesis
[41,61] but is also necessary for avoiding the entry into the
program of apoptosis [62]. Although glucose-mediated lipogenesis
was severely affected by SCD1 inhibition, several lines of evidence
suggest that the abnormally low cell proliferation rate in SCD1-
ablated cells was not caused by a deficit in the availability of
glucose or the glycolysis-derived products. Supraphysiological
concentrations of glucose or pyruvate (the final product of
glycolysis) could not restore growth. In addition, AMPK, which
was activated in slowly proliferating SCD1-deficient cells, is known
to upregulate glucose uptake and glycolysis [25]. Altogether, these
results suggest that in cells with reduced SCD1 activity the
decreased de novo synthesis of lipids, as well as the parallel
suppression of cell growth, were not due to the deficient
production of pyruvate from glycolysis.
In our SCD1-deficient cellular models, we observed that fatty
acid synthesis was downregulated, suggesting that this may be an
adaptive inhibitory metabolic response to limit the potential harm
of excess SFA accumulation when the conversion of SFA to
MUFA is blocked. Several findings support this antilipotoxic
mechanism. For instance, forcing fatty acid synthesis with citrate
produced a greater increase in the formation of SFA in SCD1-
deficient when compared to normal cells and a more profound
decrease in cell proliferation. In addition, exogenously added
citrate enhanced the effect of the SCD inhibitor on the
proliferation of A549 and H1299 cells. In line with these
observations, we have previously shown that SCD1-deficient cells
are more sensitive to the induction of apoptosis by exogenously
added SFA [19]. Other experimental conditions employed in our
experiments to activate lipogenesis such as the pharmacological
inhibition of AMPK further depressed the low proliferation rate of
cancer cells with reduced levels of SCD1. Remarkably, the
pharmacological activation of AMPK rescued the cellular
proliferation in SCD1-ablated cells. A protective role of AMPK
Figure 9. Hypothetical mechanism of regulation of lipid
synthesis by SCD1 in human cancer cells. ACC, acetylCoA
carboxylase; ACL, ATP citrate lyase; AMPK, AMP-activated protein
kinase; CE, cholesterol esters; FAS, Fatty acid synthase; PL, phospholip-
ids, SCD1, Stearoyl-CoA Desaturase 1; TAG, triacylglycerols.
doi:10.1371/journal.pone.0006812.g009
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cytotoxicity has also been reported in normal cells, including
astrocytes, pancreatic b-cells, and muscle [63–65], suggesting that
a block in fatty acid biosynthesis when SFA are abundant may
represent a ubiquitous safeguard mechanism.
We have previously reported that stable knockdown in SCD1
gene expression reduces Akt activity in cancer cells [20],
suggesting an overall shift towards cellular catabolism, which is
incompatible with cellular growth and proliferation. Here, we
have shown that genetic and pharmacological inhibition of SCD1
triggers the activation of AMPK and impairs de novo fatty acid
synthesis from glucose. Based on current results and previous data
[19,20], we postulate that by controlling the levels of SFA through
conversion into MUFA, SCD1 modulates the rate of fatty acid
synthesis and consequently the overall biosynthesis of glycerolipids
(Figure 9). SCD1 regulates the biosynthesis of fatty acids by at least
two mechanisms: 1) the regulation of the cellular content of
palmitic acid, which is a powerful negative regulator of ACC
activity [49], and 2) by controlling the phosphorylation status and
hence the activation of AMPK, which in turn phosphorylates
ACC reducing the enzyme activity and the overall rate of
lipogenesis in cells. Additionally, SCD1 may prevent the harmful
effects of excess SFA that result from constitutively active fatty acid
synthesis in cancer cells [40]. Finally, by converting the excess SFA
into MUFA, especially oleic acid, SCD1 may be able to enhance
the activity of several signaling pathways, such as Akt and PKC,
that are activated by oleate [43,66,67].
In conclusion, we have added evidence that SCD1 activity can
modulate lipogenesis and the signaling pathways that control
metabolism in cancer cells. This results in SCD1 playing a major
role in cancer cell proliferation and survival as well as in tumor
formation and progression. From a clinical perspective, inhibiting
or ablating SCD1 may represent a promising therapeutic
approach for treating deadly and widespread forms of cancer
such as lung and breast cancers.
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